President-Elect Trump to Pick Mehmet Oz to Head CMS
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Nov. 19, 2024 -- President-elect Donald Trump says he will nominate Mehmet Oz, M.D., to head the Centers for Medicare & Medicaid Services.
In a statement, Trump said that Oz will "work closely with Robert Kennedy Jr. to take on the illness industrial complex, and all the horrible chronic diseases left in its wake," The New York Times reported. Trump also remarked that Oz had "won nine Daytime Emmy Awards hosting 'The Dr. Oz Show,' where he taught millions of Americans how to make healthier lifestyle choices."
Oz, the son of Turkish immigrants, worked as a heart surgeon before helming a hugely successful daytime talk show, focused on health and medicine, from 2009 through 2022. He went on to lose a 2022 bid to represent Pennsylvania in the Senate to Democrat John Fetterman.
Oz emerged as a conservative firebrand during and after the pandemic, railing against policies he claimed "took away our freedom." During the pandemic, he was a vocal supporter of now-discredited COVID-19 "treatments" such as hydroxychloroquine and chloroquine.
Earlier in his career, Oz was forced to testify before Congress for promoting miracle weight-loss pills without any proof of efficacy.
In 2020, Oz penned an opinion column in Forbes in which he called for a form of universal health coverage in which any American not covered by Medicaid would be enrolled in a private Medicare Advantage plan. An "affordable 20 percent payroll tax" would pay for the coverage, he wrote.
The New York Times Article
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.